Generex Biotechnology Corporation (GNBT), the leader in drug delivery for metabolic diseases affecting the inner lining of the mouth, announced that the Ministry of Health of the United Arab Emirates has issued a non-object letter regarding the importation of Generax’s Oral-lyn drug. The Manager of United Arab Emirates indicated that the importation of Generex’s Oral-lyn drug can be accomplished through the issuance of a purchase order from the Imperial College London Diabetes Centre.
The Imperial College London Diabetes Centre is a leading diabetes treatment and resource center, supported by the Zayed Military Hospital. This Centre is currently treating approximately 5,000 patents. According to the International Diabetes Federation, the United Arab Emirates has the second highest rate of diabetes in the world, affecting over 20% of all residents.
Anna Gluskin, President & CEO of Generex, stated “We are pleased with the progress made by our Leosons General Trading Company. This step is significant in that it allows the Company to introduce Generex Oral-lyn into the Middle East via an established organization with a strong diabetes treatment program. We anticipate that this model will serve the purpose of demonstrating the product’s safety and efficacy to other health agencies within the Middle East.”
Let us hear your thoughts below:
